EP1156785A1 - Compositions a dissolution instantanee - Google Patents

Compositions a dissolution instantanee

Info

Publication number
EP1156785A1
EP1156785A1 EP00905188A EP00905188A EP1156785A1 EP 1156785 A1 EP1156785 A1 EP 1156785A1 EP 00905188 A EP00905188 A EP 00905188A EP 00905188 A EP00905188 A EP 00905188A EP 1156785 A1 EP1156785 A1 EP 1156785A1
Authority
EP
European Patent Office
Prior art keywords
composition according
carbohydrate polymer
rapidly
tablets
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00905188A
Other languages
German (de)
English (en)
Inventor
Glen Patrick Martyn
Camilo Colaco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Drug Delivery Ltd
Original Assignee
Quadrant Healthcare UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Healthcare UK Ltd filed Critical Quadrant Healthcare UK Ltd
Publication of EP1156785A1 publication Critical patent/EP1156785A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Definitions

  • the present invention relates to rapidly-soluble compositions.
  • the compositions are suitable for use as vehicles for the delivery, e.g. the mucosal or oral delivery, of bioactive substances.
  • the compositions are also suitable for use as delivery vehicles for active substances requiring rapid release.
  • Background of the Invention The most common pharmaceutical dosage form is the tablet.
  • the main limitations of tablets are poor patient compliance due to the difficulty in swallowing tablets and the difficulty in achieving effective dissolution, to release the bioactive contents.
  • a number of approaches have been used, including effervescent tablets using a variety of volatile material-generating systems, chewable tablets, disintegrants and wic ing agents.
  • compositions have been formulated using rapidly-soluble matrices. These are especially useful for oral administration, such as for the lingual, sublingual or buccal delivery of drugs.
  • rapidly-soluble solid dosage forms are made by aliquoting a slurry of therapeutic agent, solvent, gelatin and other excipients into preformed depressions. The liquid is then frozen and the solvent removed by sublimation, typically freeze-drying. The resulting tablet has an open porous matrix that dissolves rapidly on contact with saliva at body temperature in the mouth.
  • This dosage form marketed by R.P.Scherer as Zydis®, has enjoyed commercial success, for instance, as in the Feldene Melt® tablets distributed by Pfizer.
  • This type of delivery vehicle allows rapid dissolution of the delivery vehicle on exposure to moisture. Consequently, the tablet dissolves almost immediately upon contact with mucosal surfaces.
  • this format enjoys a large market, it has the drawback of containing gelatin.
  • Gelatin has the potential of contamination and is unsuitable for the treatment of vegetarians.
  • the hygroscopicity of this gelatin formulation also means that Zydis® tablets have to be stored in moisture-resistant packs. The tablets quickly give rise to an unacceptable "sticky" mouth-feel resulting from the poor solubility of gelatin below 37°C, and accentuated by moisture uptake of the freeze-dried gelatin. Following buccal delivery, the mouth should not be washed out for 3-5 minutes.
  • EP-A-0357665 and US-A-4855326 describe therapeutic vehicles made from cotton candy. These have the advantages, of cost and simpler, more flexible processing, over Zydis® tablets. However, there are significant problems with the development of validated methods of compacting the candy floss into tablets and with the hygroscopicity of the tablets formed. Further, the tablets exhibit much slower dissolution than Zydis®, which precludes their use in buccal delivery formats which are possible with the latter.
  • US-A-4623394 discloses compressed tablets comprising pullulan and a gum-like heteromannan. The intention is to provide gradual disintegration. Even in a control experiment, without the heteromannan, the compressed tablet took over 2 hours to achieve 100% release. Summary of the Invention
  • the present invention is based on the surprising discovery that pullulan or HES (hydroxyethyl starch) can satisfactorily be used as a replacement for gelatin, in tablets of the Zydis® type. This is despite the fact that attempts to use most carbohydrates and carbohydrate polymers, to form such matrices, including those proposed as potential substitutes for gelatin in the prior art, did not result in the production of tablets that were comparable to Zydis®.
  • Pullulan (which is described herein by way of example only) provided instantaneous dissolution and stablility at ambient temperatures and humidities, thus enabling its use in solid delivery forms as well as reducing the requirements and costs for water-resistant packaging for such delivery forms.
  • a rapidly soluble, open matrix of a carbohydrate polymer can be formed by removal of solvent from a solution containing the carbohydrate polymer and any other component(s) , the solution being provided as a single dosage aliquot in a mould corresponding to the desired shape. It appears that materials such as pullulan can readily provide a shaped body that is not only readily invaded by water, but also low friability. Description of the Invention
  • the present invention encompasses methods of making rapidly-soluble matrices of sugar (of which pullulan is an example, used herein for illustration) capable of dissolution in minimal volumes of aqueous solvent and of sufficient structural integrity to be handled as discrete units containing actives.
  • These products are suitable for use in any applications that require fast-dissolving solid formulations. They are particularly suitable for use in mucosal delivery formulations, such as tablets for per-oral delivery, that dissolve in saliva.
  • pullulan, any necessary or desirable excipients and active agent to be delivered are mixed in a liquid (in which one or more of the components may be soluble) , frozen, e.g. in individual dosage aliquots, and then lyophilised, to remove the solvent and yield a rapidly-soluble matrix containing the active.
  • a liquid in which one or more of the components may be soluble
  • the water or other solvent may also be removed by sublimation or evaporation.
  • the liquid may be frozen as part of a continuous process of lyophilisation.
  • Products of the invention comprise matrices that are soluble not just at body temperatures but also at ambient and lower temperatures. They are thus suitable not just for oral or buccal delivery as solid matrices but also as soluble matrices for rapid dissolution in aqueous solvent prior to administration.
  • the latter formulations may be combined with other excipients and formulations that aid rapid disintegration and dissolution of solid matrices including effervescent couples.
  • a wide variety of bioactive materials are suitable for use in accordance with the present invention, including therapeutic and prophylactic agents.
  • the delivery vehicle and methods of the present invention provide for a variety of dosing schemes for delivery of the bioactive material and are suitable for both veterinary and human applications.
  • any suitable excipient may be used. Many examples will be well known to those skilled in the art. Criteria for the choice of excipients include their effects on the process for obtaining the rapidly-soluble matrix, or the physical or organoleptic characteristics of the matrix.
  • the product is a confectionery product and the excipients may include flavoring agents, food dyes, stabilisers and the like.
  • the product is a therapeutic composition comprising pharmaceutical excipients as well as biologically active agents such as drugs.
  • Excipients suitable for use herein include other carbohydrates including sugars, sugar alcohols, straight- chain polyalcohols and non-reducing glycosides of polyhydroxy compounds.
  • the preferred sugar alcohols are mannitol and xylitol.
  • the glycosides are preferably monoglycosides, in particular the compounds obtained by reduction of disaccharides such as lactose, maltose, lactulose and maltulose.
  • the glycosidic group is preferably a glucoside or a galactoside and the sugar alcohol is preferably sorbitol (glucitol) .
  • maltitol (4-O- ⁇ -D-glucopyranosyl-D-glucitol)
  • lactitol (4-O- ⁇ -D-galactopyranosyl-D-glucitol)
  • iso- maltulose palatinit (a mixture of GPS, ⁇ ⁇ -D-glucopyranosyl-1- 6-sorbitol , and GPM, ⁇ -D-glucopyranosyl-l-6-mannitol)
  • palatinit a mixture of GPS, ⁇ ⁇ -D-glucopyranosyl-1- 6-sorbitol , and GPM, ⁇ -D-glucopyranosyl-l-6-mannitol
  • GPM ⁇ -D-glucopyranosyl-6-mannitol
  • Suitable carbohydrates include, but are not limited to, lactose, , ⁇ , ⁇ and o., ⁇ -trehaloses, raffinose, palatinit, GPS, stachyose, mellibiose and mannotriose.
  • the excipients can include those found in confectionaries.
  • a low molecular weight carbohydrate e.g. a mono-, di-, tri- or tetrasaccharide
  • the amount of therapeutic (or bioactive) agent should be suffficient to yield a final product that contains an effective amount of the therapeutic agent.
  • the products obtained are suitable for use as pharmaceuticals, other medical applications such as diagnostics, environmental applications, agricultural and industrial use.
  • An effective amount of a bioactive agent is one which causes amelioration or palliation of the condition to be treated.
  • bioactive materials examples include any pharmaceutical agents, including anti-inflammatory drugs, analgesics, antiarthritic drugs, antispasmodics, anti-depressants, antipsychotics, tranquilisers, anti-anxiety drugs, narcotic antagonists, anti-Parkinsonism agents, cholinergic agonists, chemotherapeutic drugs, immunosuppressive agents, antiviral agents, antibiotic agents, appetite suppressants, antiemetics, anticholinergics, antihistaminics, anti- migraine agents, coronary, cerebral or peripheral vasodilators, hormonal agents, contraceptives, antithrombotic agents, diuretics, antihypertensive agents, cardiovascular drugs and opioids.
  • pharmaceutical agents including anti-inflammatory drugs, analgesics, antiarthritic drugs, antispasmodics, anti-depressants, antipsychotics, tranquilisers, anti-anxiety drugs, narcotic antagonists, anti-Parkinsonism agents, cholinergic agonists, chemotherapeutic drugs, immunos
  • Suitable bioactive materials also include biological modifiers.
  • Such modifiers include sub ⁇ ellular compositions, cells, bacteria, viruses and molecules including lipids, organics, proteins and peptides (synthetic and natural) , peptide mimetics, hormones (peptide, steroid and corticosteroid) , D and L amino acid polymers, oligosaccharides, polysaccharides , nucleotides, oligonucleotides and nucleic acids, including DNA and RNA, protein-nucleic acid hybrids, small molecules and physiologically active analogues thereof.
  • the modifiers may be derived from natural sources or made by recombinant or synthetic means and include analogues, agonists and homologues.
  • protein refers also to peptides and polypeptides.
  • proteins include enzymes, biopharmaceuticals, growth hormones, growth factors, insulin, monoclonal antibodies, interferons, interleukins and cytokines.
  • Organics include pharmaceutically active chemicals with amino, imino and guanidino groups.
  • Suitable steroid hormones include estrogen, progesterone, testosterone and physiologically active analogues thereof. Numerous steroid hormone analogues are known in the art and include estradiol, SH-135 and tamoxifen.
  • nucleic acids includes any therapeutically effective nucleic acids known in the art including DNA, RNA and physiologically active analogues thereof.
  • the nucleotides may encode single genes or may be any vector known in the art of recombinant DNA including plasmids, retroviruses and adeno-associated viruses.
  • the nucleotides are administered in the powder form of the solid dose vehicle. Compositions containing prophylactic bioactive materials and carriers therefore are further encompassed by the invention.
  • compositions include immunogens such as vaccines.
  • Suitable vaccines include live and attenuated viruses, nucleotide vectors encoding antigens, heat-shock protein complexes, bacteria, antigens, antigens plus adjuvants, and haptens coupled to carriers.
  • vaccines effective against diphtheria, tetanus, pertussis, botulinum, cholera, Dengue, Hepatitis A, C and E, hemophilus influenza B, herpes virus, Helicobacter pylori , influenza, Japanese encephalitis, meningococci A, B and C, measles, mumps, papilloma virus, pneumococci, polio, rubella, rotavirus, respiratory syncytial virus, Shigella, tuberculosis, yellow fever and combinations thereof.
  • Vaccines may also be produced by molecular biology techniques to produce recombinant peptides or fusion proteins containing one or more portions of a protein derived from a pathogen.
  • fusion proteins containing the antigen of interest and the B subunit of cholera toxin have been shown to induce an immune response to the antigen of interest. See Sanchez et al (1989), Proc. Natl. Acad. Sci. USA 86:481-485.
  • the immunogenic composition contains an amount of an adjuvant sufficient to enhance the immune response to the immunogen.
  • Suitable adjuvants include aluminum salts, squalene mixtures (SAF-1) , muramyl peptide, saponin derivatives, mycobacterium cell wall preparations, heat-shock proteins, monophosphoryl lipid A, mycolic acid derivatives, nonionic block copolymer surfactants, Quil A, cholera toxin B subunit, polyphosphazene and derivatives, and immunostimulating complexes (ISCOMs) such as those described by Takahashi et al (1990), Nature 344:873-875.
  • itogenic components of Freund's adjuvant can be used.
  • the immunologically effective amounts of the immunogens must be determined ertlpirically.
  • Factors to be considered include the immunogenicity, whether or not the immunogen will be complexed with or covalently attached to an adjuvant or carrier protein or other carrier, route of administration and the number of immunising doses to be administered. Such factors are known in the vaccine art and it is well within the skill of immunologists to make such determinations without undue experimentation.
  • the present invention encompasses compositions and methods of making the compositions. Although singular forms may be used, more than one carbohydrate polymer and more than one excipient and active substance may be present. Determination of the effective amounts of these compounds is within the skill of one in the art.
  • Example 1 The exact processing conditions will be depend on the formulation and equipment and can be readily determined by one skilled in the art. Excipients may be added to enhance the processing and/or to tailor the physical or organoleptic properties of the compositions that are obtained. The following Examples illustrate the invention. Example 1
  • the solid matrices in the blister packs were of sufficient non- friability (3.52%) to be removed as an intact single dosage unit from the wells of the blister pack and dissolved instantaneously in water ( ⁇ 2sec) at room temperature (15-20°C) , even after a week's storage of the blisters on the bench at ambient temperatures and humidities.
  • the friability of commerical Zydis® tablets was 2.8% and the dissolution time c.8 sec.
  • the mean water content of the solid matrices was 3.24% (SD 0.19%) and the mean content uniformity of active 98.62% (SD 0.73%).
  • Example 2 The procedure of Example 2 was repeated, but using, instead of diltiazem, 20% acyclovir (model hydrophobic active) .
  • the solid matrices obtained in the blister packs were of sufficient non-friability (2.69%) to be removed as an intact single dosage unit from the wells and dissolved instantaneously in water ( ⁇ 2sec) at room temperature (15-20°C) , even after a week's storage of the blisters on the bench at ambient temperatures and humidities.
  • the mean water content of the solid matrices was 4.75% (0.11%) and the mean content uniformity of active 105.63% (SD 0.96%).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition mise sous forme, comprenant une matrice ouverte, à dissolution instantanée, d'un hydrate de carbone polymère. Une telle composition peut être obtenue par élimination du solvant d'une solution contenant l'hydrate de carbone polymère et d'autre(s) composant(s), une partie aliquote de la solution étant introduite, en tant que dose unique, dans un moule correspondant à la forme recherchée.
EP00905188A 1999-02-22 2000-02-22 Compositions a dissolution instantanee Withdrawn EP1156785A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9904049.5A GB9904049D0 (en) 1999-02-22 1999-02-22 Rapidly-soluble compositions
GB9904049 1999-02-22
PCT/GB2000/000630 WO2000050013A1 (fr) 1999-02-22 2000-02-22 Compositions a dissolution instantanee

Publications (1)

Publication Number Publication Date
EP1156785A1 true EP1156785A1 (fr) 2001-11-28

Family

ID=10848274

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00905188A Withdrawn EP1156785A1 (fr) 1999-02-22 2000-02-22 Compositions a dissolution instantanee

Country Status (6)

Country Link
EP (1) EP1156785A1 (fr)
JP (1) JP2002537322A (fr)
AU (1) AU2681500A (fr)
CA (1) CA2363126A1 (fr)
GB (1) GB9904049D0 (fr)
WO (1) WO2000050013A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4203322B2 (ja) * 2001-04-26 2008-12-24 株式会社林原生物化学研究所 プルラン高含有成形物とその製造方法並びにその用途
CA2504610C (fr) * 2002-11-12 2012-02-21 Elan Pharma International Ltd. Formes posologiques solides a desintegration rapide non friables et comprenant du pullulane
CN100366294C (zh) 2004-04-30 2008-02-06 量子高科（北京）研究院有限公司 一种口腔速溶制剂及其生产方法
TR200907338A1 (tr) * 2009-09-28 2011-04-21 Yedi̇tepe Üni̇versi̇tesi̇ Doğal bileşenler içeren bir film şeridi.
US10548839B2 (en) 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
EP2815743A1 (fr) * 2013-06-21 2014-12-24 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations comprenant du ceftibutène
CA2931862C (fr) 2013-11-08 2024-01-23 Carlos Filipe Procede de stabilisation de molecules sans refrigeration a l'aide de polymeres solubles dans l'eau et ses applications dans la realisation de reactions chimiques
JPWO2017170763A1 (ja) * 2016-04-01 2019-01-10 株式会社クレハ 崩壊錠及びその製造方法
US11040015B2 (en) * 2017-10-16 2021-06-22 Mcmaster University Method of long-term preservation of chemical and biological species using sugar glasses
WO2019153080A1 (fr) 2018-02-06 2019-08-15 Ontario Institute For Cancer Research (Oicr) Inhibiteurs de l'interaction protéine-protéine du domaine bcl6 btb et leurs utilisations
US20230158047A1 (en) 2020-04-16 2023-05-25 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1022021A1 (fr) * 1997-10-09 2000-07-26 SSP Co., Ltd. Preparations solides rapidement solubles
WO2000044351A1 (fr) * 1999-01-27 2000-08-03 R.P. Scherer Corporation Formes posologiques a diffusion rapide exemptes de gelatine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6425870A (en) * 1987-04-30 1989-01-27 Ajinomoto Kk Support for anastomosis or bonding of living body
US5215756A (en) * 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
JP2919771B2 (ja) * 1995-04-17 1999-07-19 佐藤製薬株式会社 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤
BR9609188A (pt) * 1995-06-07 1999-05-11 Quadrant Holdings Cambridge Métodos para incorporar substâncias de modo estável dentro de matrizes de vidro espumado secas e composições obtidas desse modo
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1022021A1 (fr) * 1997-10-09 2000-07-26 SSP Co., Ltd. Preparations solides rapidement solubles
WO2000044351A1 (fr) * 1999-01-27 2000-08-03 R.P. Scherer Corporation Formes posologiques a diffusion rapide exemptes de gelatine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0050013A1 *

Also Published As

Publication number Publication date
JP2002537322A (ja) 2002-11-05
AU2681500A (en) 2000-09-14
WO2000050013A1 (fr) 2000-08-31
CA2363126A1 (fr) 2000-08-31
GB9904049D0 (en) 1999-04-14

Similar Documents

Publication Publication Date Title
EP0773781B1 (fr) Systemes d'administration de substances solides, pour la liberation controlee de molecules incorporees dans ces substances et procedes de fabrication de ces systemes
AU713599B2 (en) Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
US5762961A (en) Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
WO2000013680A2 (fr) Compositions d'hydrates ce carbone amorphes filamenteux et vehicules d'administration therapeutique en etant faits
US6893657B2 (en) Solid dose delivery vehicle and methods of making same
KR100852015B1 (ko) 무젤라틴의 급속 분산성 제형
US20050186254A1 (en) Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
US5958455A (en) Oral solid dosage forms, methods of making same and compositions thereof
EP1156785A1 (fr) Compositions a dissolution instantanee
JPS58113124A (ja) 固体成形品
WO2006045830A1 (fr) Forme galenique solide fortement poreuse et a desintegration rapide et procede de production associe comportant la preparation d'une poudre et une etape de lyophilisation
BG100749A (bg) Бързо разтваряща се орална дозирана форма
PL169807B1 (en) Method of making dimeticon containing tablet for sucking
RU2177785C2 (ru) Твердые системы доставки для контролируемого высвобождения включенных в них молекул и способы их приготовления
RU97103529A (ru) Твердые системы доставки для контролируемого высвобождения включенных в них молекул и способы их приготовления
AU688557C (en) Solid delivery systems for controlled release of molecules incorporated therein and methods of making same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010813

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ELAN DRUG DELIVERY LIMITED

17Q First examination report despatched

Effective date: 20030704

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: QUADRANT DRUG DELIVERY LIMITED

R17C First examination report despatched (corrected)

Effective date: 20030704

R17C First examination report despatched (corrected)

Effective date: 20030704

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070117